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Abstract
Background: The majority of cases with severe pulmonary alveolar proteinosis (PAP) are caused by auto-antibodies
against GM-CSF. A multitude of genetic and exogenous causes are responsible for few other cases. Goal of this
study was to determine the prevalence of GATA2 deficiency in children and adults with PAP and hematologic
disorders.
Methods: Of 21 patients with GM-CSF-autoantibody negative PAP, 13 had no other organ involvement and 8 had
some form of hematologic disorder. The latter were sequenced for GATA2.
Results: Age at start of PAP ranged from 0.3 to 64 years, 4 patients were children. In half of the subjects
GATA2-sequence variations were found, two of which were considered disease causing. Those two patients
had the typical phenotype of GATA2 deficiency, one of whom additionally showed a previously undescribed
feature – a cholesterol pneumonia. Hematologic disorders included chronic myeloic leukemia, juvenile
myelo-monocytic leukemia, lymphoblastic leukemia, sideroblastic anemia and two cases of myelodysplastic syndrome
(MDS). A 4 year old child with MDS and DiGeorge Syndrome Type 2 was rescued with repetitive whole lung lavages
and her PAP was cured with heterologous stem cell transplant.
Conclusions: In children and adults with severe GM-CSF negative PAP a close cooperation between pneumologists
and hemato-oncologists is needed to diagnose the underlying diseases, some of which are caused by mutations of
transcription factor GATA2. Treatment with whole lung lavages as well as stem cell transplant may be successful.
Background
Pulmonary alveolar proteinosis (PAP) is a rare disorder
characterized by the progressive accumulation of surfactant
in the alveoli of the lungs, leading to hypoxemic respiratory
failure and, in severe cases, to death [1]. PAP is caused by
(i) genetic diseases which result in dysfunction of surfactant
or surfactant production (SFTPC, SFTPB, ABCA3, TTF1
deficiency) mainly presenting during infancy, by (ii) disrup-
tion of GM-CSF signaling from mutations in the receptor
(GM-CSFRa, GM-CSFRb) or from acquired autoantibodies
against GM-CSF, and by (iii) disorders that presumably im-
pair surfactant clearance because of abnormal numbers or
defective phagocytic functions of alveolar macrophages [2].
The latter are caused by inhaled particles or by hematologic
disorders affecting macrophage precursors.
A broad spectrum of hematologic disorders have been
associated with PAP, most frequently myelodysplastic syn-
drome (MDS), and more rarely acute (AML) and chronic
myeloid leukaemia (CML), myelofibrosis, acute lymphoid
leukaemia (ALL), adult T-cell leukaemia, aplastic anemia,
lymphoma, multiple myeloma, plasmacytoma, essential
thrombocytosis [3], congenital dyserythropoietic anemia
[4], and status after unrelated stem cell transplant [5, 6].
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Up to now only mutations in one specific gene -GATA2-
have been associated with this form of PAP.
GATA2 is a zinc finger transcription factor essential for
differentiation of immature hematopoietic cells [7]. Among
many other functions GATA2 regulates the phagocytosis of
alveolar macrophages [8]. Alveolar macrophages treated
with the sense GATA-2 expression construct show an in-
crease in their phagocytic activity by up to 280 % compared
to the antisense construct [9]. GATA2 deficiency is a re-
cently described disorder of hematopoiesis, lymphatics, and
immunity, caused by heterozygous mutations leading to
haplo-insufficiency of the transcription factor GATA2. The
disease presents with a complex array of diagnoses and
symptoms of varying extent including MDS, AML, chronic
myelomonocytic leukemia (CMML), severe viral, dissemi-
nated mycobacterial and invasive fungal infections, pul-
monary arterial hypertension, warts, panniculitis, human
papillomavirus (HPV) positive tumors, Epstein-Barr virus
(EBV) positive tumors, venous thrombosis, lymphedema,
sensorineural hearing loss, miscarriage and hypothyroidism
[6]. PAP has been reported in about 18 % of all subjects
with GATA2 deficiency [6, 10]. However, not much is
known on the severity and clinical course of PAP in these
subjects, which were exclusively adults. Pneumologists
treating patients with severe PAP not caused by autoanti-
bodies against GM-CSF frequently do not know the cause
of these rare conditions [11].
Here, we investigate a cohort of children and adults
with severe and chronic PAP and hematologic disease
for the presence of GATA2 mutations. GATA2 muta-
tions were identified in a minority of patients only. One
child with a GATA2 variant was successfully treated ini-
tially by therapeutic whole lung lavages (WLL) and even-
tually by stem cell transplant.
Methods
All subjects with PAP diagnosed based on the character-
istic phenotype by lung biopsy or bronchoalveolar lavage
(BAL) and CT scan findings were identified from the
kids-lung-register (http://www.kinderlungenregister.de/
index.php/en/) within the child-EU project (European
Register and Biobank on Childhood Interstitial Lung
Diseases, European Commission, FP7, GA 305653).
In order to differentiate subgroups of PAP, all patients
with GM-CSF-Ra or Rb mutations [12] and a high GM-
CSF autoantibody level were excluded. 21 subjects were
identified of whom 13 (11 adults, 2 children) had pulmon-
ary involvement only. 8 subjects suffered from PAP and a
hematologic disease - diagnosed by standard procedures-
and were selected for further analysis (Fig. 1).
The GATA2 gene was analysed by Sanger sequencing.
Genomic DNA was isolated from EDTA blood samples
using the QIAamp DNA Blood Mini Kit (Qiagen) and PCR
amplified using HotStarTaq polymerase (Qiagen). PCR
products were purified with the MinElute 96 UF PCR Puri-
fication Kit (Qiagen). Primers used for PCR and sequencing
reactions are shown in Table 1. Sequencing was performed
by GATC Biotech AG (Konstanz, Germany).
In subject 4 800 ng of genomic DNA extracted from for-
malin fixed tissue were fragmented to an average size of
200 bp and desired fragment sizes were obtained with
Agencourt® AMPure® XP beads (Beckman Coulter). Se-
quencing libraries were prepared using Accel-NGS-1S Li-
brary Kit (Swift Biosciences, Ann Harbor, MI), sequenced
on the HiSeq 1500 (Illumina) and aligned to the human
genome assembly (hg19). The GATA2 locus was covered
by 86 reads.
Follow-up data of the patients were collected until
October 2014. The study was approved by the institutional
review board, the ethics commission of the medical faculty
of the Ludwig-Maximilians University, Munich, Germany
(EK 026–06). All parents or guardians gave their written
informed consent, the children gave assent.
Results
Age at onset of PAP ranged from 0.4 to 64 years. Half of
the patients were children (Table 2). Beside chronic respira-
tory insufficiency due to PAP, all patients suffered from
recurrent respiratory tract infections or exacerbations.
These were mainly common cold viral infections, in some
cases non-tuberculous mycobacteria, herpes simplex virus
(HSV), and cytomegalovirus (CMV) were identified. All pa-
tients were immunodeficient: in three patients primary
immunodeficiency syndromes were identified: two with a
monocyte deficiency not further specified (no. 2, 4) and one
with a Di George type II syndrome with combined
Fig. 1 Study design and flow of subjects retrieved from the
kids-lung-register data base and biobank. Abbreviations: PAP,
pulmonary alveolar proteinosis; CML, chronic myeloic leukemia,
JMML, juvenile myelo-monocytic leukemia; cALL, common acute
lymphoblastic leukemia; MDS, myelodysplastic syndrome
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Table 1 Sequences of primers used for amplification of the GATA2 gene
Exon Forward Reverse
#1 CCC GCA AAG TGA TGT CG CAA ACG GAC CAA GCG ATT C
#2 ACC TCG TGG TGG GAC TTT G GAT CCT ACA TCC GGG AAG C
#3/1 GTC CCT AGC TCT GCC TAC CC CTC CTC GGG CTG CAC TAC
#3/2 ACC TTT TCG GCT TCC CAC CTC TCC CAA GTC ACA GCT CC
#4 GAC TCC CTC CCG AGA ACT TG TGT AAT TAA CCG CCA GCT CC
#5 GTG GAG CGA GGG TCA GG CAC AAA GCG CAG AGG TCC
#6/1 AGG AAT GTT GCT GGA GGA AG AAC TGT CCA TGC AGG AAA CC
#6/2 GAC ACC ACT CCT GCC AGC ACA CAG TCA CAG CAG CTT CG
#6/3 TGG AGG GCA GAG ACA ATC AC AGC AGG GAC ACA GCC TCT C
#6/4 CTT TGC TGC CCT TGG TTT C AAT CTG GCT GCC CAA ATT C








Out-come Final diagnosis and likely
cause of PAP
1 F 64 Chronic respiratory
insufficiency, PAP,
inactive TBC, ARDS
Diffuse ground glass with clear
interstitial septal thickening (crazy
paving pattern), bilateral alveolar
consolidations
Oxygen, WLL (2) 66 dead CML, karyotype 46XX
t(9,22) (q34,q11) 25, CD
2+, renal failure














3 M 0.6 Infection, tachydyspnea
(7 months old), hypoxia,
PAP (1.7 y)












Monosomy 7, 2x SCT,
intestinal, hepatic, cuta-
neous GVHD




Diffuse ground glass, interstitial
markings, scattered alveolar
opacities









5 F 6 PAP Ground glass, interstitial
pneumonia




6 F 59 Dyspnea, respiratory
insufficiency, PAP
Diffuse ground glass, interstitial
septal thickening (crazy paving),
markedly basal, with traction
bronchiectasis
Oxygen, WLL (1) 59 dead MDS
7 F 4 Recurrent airway
infections; chronic
hypoxic failure, PAP
Alveolar opacities in almost all
lung areas, see Fig. 2
Oxygen, WLL (14) 7.3 healthy MDS, DiGeorge
Syndrome Type 2,
Monosomy 7, Trisomy 8
(SCT)
8 M 0.33 CMV infection,
respiratory failure, PAP
Ground glass opacities with
interstitial septal thickening (crazy
paving pattern), alveolar
consolidations bilaterally in the
lower parts
Oxygen, WLL (11) 2 sick-
better
Sideroblastic anemia
Abbreviations: ARDS, acute respiratory distress syndrome; CML, chronic myeloid leukemia; CMV, cytomegalovirus; dis., disease; GVHD, graft versus host disease;
HSV, herpes simplex virus; MDS, myelodysplastic syndrome; PAP, pulmonary alveolar proteinosis; pulm., pulmonary; SCT, stem cell transplant; TB, tuberculosis,
WLL, whole lung lavage; y, years; number in (), number of WLL
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immunodeficiency (no. 7); all three patients are described
below in detail. In the other patients, immunodeficiency
was secondary to the hematologic condition (CML, juven-
ile myelomonocytic leukemia (JMML), c-acute lympho-
blastic leukemia (cALL), MDS) and/or therapeutic
interventions (steroids, immunosuppressant medication).
The hallmark of all patients of this study was severe
PAP with continuous need of oxygen (Table 2). All but
two subjects (no. 4, 5) were treated symptomatically
with repetitive therapeutic WLL to improve respiratory
insufficiency. Treatment was eventually not successful
in 3 patients who died from respiratory failure, compli-
cated by infection or acute respiratory distress syn-
drome (ARDS).
Autoantibodies against GM-CSF were determined in
order to characterize PAP further, they were negative in
all patients (Table 3). Serum levels of GM-CSF were not
significantly increased in the patients with serum avail-
able. 4 of the 8 patients had sequence anomalies in
GATA2 (Table 3). Two of these, a synonymous variant
and a missense variant were predicted not to be dam-
aging by Polyphen-2 [13] and SIFT [14]. The other two
were heterozygous point mutations predicted to be dele-
terious, both of these patients had a phenotype charac-
teristic for GATA2 deficiency.
The courses of cases 2, 4, 7 and 8 are reported in more
detail to illustrate characteristic presentations.
Case no. 2
A 34 year old male patient presented with disseminated
Mycobacterium avium intracellulare infection, includ-
ing the lungs, chronic labial herpes including a positive
serum HSV PCR, and M. Bowen of the skin. Cellular
immunodeficiency was suspected based on absent
monocytes; the patient was HIV-negative. 3 years later
the patient developed respiratory insufficiency, the CT
scan showed consolidations suspicious of cryptogenic
organizing or atypical pneumonia. Several courses of
antibiotic therapy were followed by two pulses of
cyclophosphamide; the patient deteriorated further,
CT scan showed bilateral interstitial thickening and
crazy-paving pattern. Open lung biopsy revealed PAP.
Bone marrow aspiration was normal. He was treated
symptomatically with WLL under ECMO (extracor-
poreal membrane oxygenation) support, developed an-
uric acute renal failure, and died from acute cardiac
failure. The patient carried the mutation p.Y377D in
the GATA2 gene.
Case no. 4
A 38 year old female patient presented with recurrent
bronchitis and sinusitis, breathlessness during exercise,
and interstitial markings on chest x-ray. An open lung
biopsy was performed, histology revealed PAP associated
with cholesterol pneumonia. Liver and bone marrow
biopsies were normal. In the following months she de-
veloped progressive peripheral edema and cardiac insuf-
ficiency with mild pulmonary hypertension. She further
developed a pseudomembranous glomerulonephritis with
nephrotic syndrome and a Pseudomonas urosepsis at
39 years. At 40 years cellular immunodeficiency was
demonstrated based on the absence of monocytes. She de-
veloped condylomatous lesions of the vulva and HPV-
associated (types 16 and 28) vulva intraepithelial neoplasia
grade 2–3 (VIN2-VIN3), which was resected. Her course
was determined by chronic respiratory failure (at rest
4LO2/min; PaO2 45 mmHg (normal > 86), normal
PaC02). However, no WLL were performed as the pa-
tient was lost on follow up at 43 years. The patient
carried the mutation p.R398W in the GATA2 gene.
Case no. 7
A 4.5 year old girl with Di George Syndrome type II
from deletion of 10p (OMIM 601362) with severe im-
munodeficiency, single right kidney, inner ear deafness,
Table 3 Laboratory results of the patients with hematologic PAP
No ID GM-CSF auto-anti-bodies in serum GM-CSF in plasma [pg/mL]
(normal 5.5 ± 7.2)a
GATA2-gene analysis Interpretation
1 153 Negative n.a. c.564 G > C ht; p.T188T Synonymous variant; C-allele
frequency of 0.09
2 163 Negative 5 c.1129 T > G ht; p.Y377D Missense mutation, deleterious
3 194 Negative n.a. Normal
4 432 Negative 2.9 c.1192C > T ht;p.R398W Missense mutation, deleterious
5 1505 Negative 0.0 Normal
6 1740 Negative 17.5 Normal
7 2334 Negative 11.5 c.490 G > A ht; p.A164T Missense variant; tolerated, minor
allele frequency of 0.24
8 2530 Negative 1.8 Normal
Abbreviations: n.a. not available
aCarraway et al. Am J Respir Crit Care Med 2000; 161: 1294–1299
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mild cognitive delay and dystrophy (BMI 12.0 kg/m2 < 1.
percentile)), presented with weight loss, dry cough and
frequent night awakenings due to acute dyspnea. The
condition deteriorated slowly. She had to sleep in an up-
right position when she was referred to our hospital at
the age of 6 years. Her oxygen saturation was 75 % with-
out and 92 % with 6 L of O2/min. She had silent breath
sounds and a reduced white blood cell count with eo-
sinophilia (1050/μl: neutrophils 8 %, lymphocytes 67 %,
monocytes 4 %, eosinophils 19 %, basophils 1 %). MDS
with refractory cytopenia (MDS-RC), cytogenetic abnor-
malities (del 10p, trisomy 8, monosomy 7) and second-
ary PAP was diagnosed. In BAL fluid elevated
eosinophils and granular eosinophilic debris, PAS +,
characteristic for PAP were seen. She was treated with
14 WLL by pulmonary artery catheter technique [15],
with good clinical and radiological response over a
period of one year (Fig. 2). A HLA-identical (10/10)
unrelated-stem cell donor was identified at the age of
10 years and she received allogeneic stem cell transplant.
Within a few weeks after transplant, PAP and respiratory
distress resolved (Fig. 2).
Case no. 8
A full-term boy with normocytic anemia (Hb 13.1 g/dL)
presented after a few weeks with paleness, fatigue, tachy-
dyspnea, and failure to thrive. At the age of four month
the hemoglobin level had decreased to 5.3 g/dL and a
sideroblastic anemia was diagnosed. No genetic cause was
identified; Pearson syndrome and mutations in ALAS2
and SLC25A38 were excluded. His bone marrow showed
massive erythroid hyperplasia with dyserythropoiesis and
marked depression of myeloid cells. Pulmonary infiltrates
were initially interpreted as pneumonia. At the age of
5 months a CMV infection was successfully treated with
ganciclovir. At 8 months he developed respiratory failure
(PaO2 60 mmHg, PaCO2 55 mmHg) with bilateral pul-
monary infiltrates. The diagnosis of PAP was made by
analysis of BAL fluid and open lung biopsy. From the age
8 to 23 months the boy underwent 11 therapeutic WLLs,
improving his general condition and gas exchange. Cur-
rently he maintains oxygen-saturation levels above 92 %
under oxygen support 0.5-1 l of O2/min). The anemia is
stable with Hb levels between 7.5 and 9.0 g/dL. The mo-
lecular cause of very rare sideroblastic anemia was not re-
vealed, the associated depression of myeloid cells was
likely the cause of PAP. GATA2 deficiency was not causal,
as the patient showed no GATA2 variant in our investiga-
tions; potential intronic variations were not investigated.
Discussion
This study shows that GATA2 mutations in patients with
hematologic diseases and severe PAP occur at a relatively
low frequency. GATA2 analysis may help to diagnose the
underlying hematologic condition. Severe PAP in children
due to MDS can be cured by stem cell transplant.
Severe PAP is a rare but serious complication of
hematologic disorders. Here we differentiated two groups
of diseases having in common a presentation with signifi-
cant chronic respiratory insufficiency and recurrent pul-
monary tract infections or exacerbations. These groups
included (i) patients with GATA2 deficiency, a protean
disorder of hematopoiesis, lymphatics, and immunity [6],
and (ii) patients with functionally or numerically reduced
alveolar macrophages and/or their respective mono-
nuclear precursors due to CML, JMML, cALL, MDS or
sideroblastic anemia in the absence of disease causing
GATA2 mutations.
GATA2 deficiency has a broad phenotype encompassing
immunodeficiency, MDS/AML, pulmonary disease, and
vascular/lymphatic dysfunction. A precise history and
knowledge of the disease course may help to select poten-
tial candidates with high confidence for specific genetic
diagnostic. GATA2 gene mutations were associated with
PAP in two cases; p.Y377D is a novel missense mutation
demonstrated here to present with the classical mono-
MAC syndrome [16]. p.R398W has previously been de-
scribed in six patients, of whom 2 had a PAP [6]. Here we
add the histopathological feature of cholesterol pneumo-
nia to this phenotype. Of interest, further heterozygous
variations in GATA2 were identified in two other subjects;
however these were predicted to be non-disease causing
(Table 3). As not all subjects with a specific GATA2 muta-
tion causing GATA2 deficiency develop PAP [6], add-
itional factors are involved which determine PAP. Patients
with the same GATA2 mutation need to be investigated
further and experimental models will help to better under-
stand the molecular defect(s) leading to PAP. Similarly, in
non-GATA2 deficient patients with PAP and hematologic
abnormalities, the mechanism of PAP development is un-
known. Currently, their PAP is presumed to be due to re-
duced monophagocytic function in the alveoli to clear
surfactant [17]. Best proof for the critical role of bone-
marrow derived alveolar macrophages for surfactant
homeostasis is provided by the correction of PAP by SCT.
This was shown here for the first time in a young child.
Shortly, i.e. within days after take of SCT, there was clear-
ing of PAP, superseding rapidly the need for therapeutic
WLLs (Fig. 1).
Here we also show that WLLs are feasible also for
children, even at very young age, with small sized air-
ways and in the presence of severe respiratory distress,
using techniques we have established previously [18].
WLL can be used to symptomatically treat all types of
PAP and to bridge until the underlying condition can be
cured or alternative treatments have been implemented.
Due to relative immune deficiency state and irrespective
of the cause, the impact of infections should be considered
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Fig. 2 Long term course of a child suffering from DiGeorge syndrome type II and PAP due to MDS with monosomy 7, trisomy 8, and a GATA2
missense variant. Successful treatment by therapeutic WLLs, and definitive treatment of the PAP by SCT. (a) clinical course (b,c) CT1 at
presentation (d,e) CT2 after first 2 whole lung lavages (f) CXR 1 before SCT (g) CXR2 7 weeks after SCT and (h) CXR3 1 year after SCT
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carefully. It is likely that with often severe respiratory tract
infections PAP may be triggered to deteriorate. Thus we
recommend early diagnosis and proper antimicrobial treat-
ment, in particular of organisms characteristic for these
often lethal conditions, including mycobacteria, nocardia,
herpes viruses, and fungi [6, 19, 20]. In addition and con-
cordant with the immune deficiency the extensive usage of
systemic corticosteroids should be cautioned, as there is so
far no evidence of their beneficial effect in PAP. Extensive
usage might enhance immune deficiency and weaken anti-
microbial defense further [15].
After confirming the diagnosis of PAP either by a com-
bination of characteristic CT scan and BAL findings and
trans-bronchial or open lung biopsy, it is important to de-
termine the etiology of PAP. As more than 90 % of PAP in
adulthood is caused by autoantibodies against GM-CSF
[1, 21, 22], this condition has to be initially excluded by
analysis of serum [23, 24]. None of our patients had in-
creased levels of GM-CSF autoantibodies. Serum levels of
GM-CSF are low in autoimmune PAP [25], whereas ele-
vated values can be found in congenital GM-CSFRa or
GM-CSFRb defects and possibly in other forms of PAP.
Thus, particularly in children these other entities need to
be excluded. In our cohort of patients with severe PAP
and hematologic diseases, serum GM-CSF level were low
to intermediate, supporting some up regulation of GM-
CSF. Next, genetic analysis of GATA2 is helpful in order
to diagnose the underlying hematologic entity more pre-
cisely, in particular in patients who meet the broad but
characteristic phenotype of GATA2 deficiency [6]. This
diagnostic algorithm for PAP will allow differentiating im-
portant subgroups and may help to identify further gen-
etic abnormalities, known or suspected to be associated
with PAP.
Conclusions
When investigating a patient with severe PAP, the pneu-
mologist should be aware of the wide range of diseases
which can cause secondary PAP and consider interdiscip-
linary involvement of a hemato-oncologist. Conversely,
hemato-oncologists should include PAP in the differential
diagnosis of respiratory failure associated with pulmonary
interstitial changes in hematologic diseases.
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